Eli Lilly and Company
The LNP PD Associate at Eli Lilly's Gene Therapy team in Boston contributes to developing lipid and targeted lipid nanoparticle-based gene therapy reagents for clinical applications. The position is part of a cross-functional effort to invent, characterize, and advance novel gene therapy platforms across multiple disease areas.
Headquarters
Indianapolis, Indiana, United States
Company Size
10001+ employees
Founded
1876
Eli Lilly and Company is a global biopharmaceutical company headquartered in Indianapolis, Indiana. It discovers, develops, manufactures and commercializes prescription medicines across therapeutic areas including diabetes, oncology, immunology, neuroscience and pain, and has a longstanding history in insulin and other major drug discoveries. Lilly invests heavily in research and clinical development and partners with biotech, academic institutions, and industry collaborators to advance biologics, small molecules, and precision medicines. The company operates global manufacturing and commercial networks and provides patient-support programs to improve access to its therapies.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Eli Lilly and Company.
Li Auto OTA Upgrade And Charging Use Test Investor Patience
1 week ago
Contract SRA / Scientist, Lipid Nanoparticle (LNP) Discovery
Addition Therapeutics
Associate Scientist/Scientist I, LNP Formulations
Flagship Pioneering, Inc.
Associate Scientist, Non Viral Delivery Technologies (Regeneron Genetics Medicines) 2
Regeneron Pharmaceuticals
Scientist, LNP Process and Development
Flagship Pioneering, Inc.
Senior Research Associate, LNP Production
MiraiBio Group at Hitachi Solutions America
Research Associate, Formulation Development
Pivotal